Anfield Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Anfield Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.95K	Hold	301	–	–	﹤0.01%	464
2025 Q4	$8.72K	Hold	301	–	–	﹤0.01%	350
2025 Q3	$8.36K	Hold	301	–	–	﹤0.01%	351
2025 Q2	$7.33K	Hold	301	–	–	﹤0.01%	335
2025 Q1	$6.25K	Hold	301	–	–	﹤0.01%	303
2024 Q4	$7.09K	Hold	301	–	–	﹤0.01%	273
2024 Q3	$7.71K	Hold	301	–	–	﹤0.01%	264
2024 Q2	$7.07K	Buy	301 +1	+0.3%	+$25	﹤0.01%	222
2024 Q1	$8.63K	Buy	+300	New	+$9.02K	﹤0.01%	163
2022 Q1	–	Sell	-12,535	Closed	-$768K	–	99
2021 Q4	$768K	Buy	12,535 +147	+1%	+$10.2K	0.26%	50
2021 Q3	$926K	Sell	12,388 -114	-0.9%	-$9.56K	0.29%	59
2021 Q2	$1.16M	Buy	12,502 +702	+6%	+$59.7K	0.44%	45
2021 Q1	$1.05M	Sell	11,800 -17,310	-59%	-$1.72M	0.42%	54
2020 Q4	$2.71M	Sell	29,110 -3,520	-11%	-$280K	1.16%	23
2020 Q3	$2.08M	Buy	+32,630	New	+$1.91M	1.2%	20
2020 Q1	–	Sell	-600	Closed	-$20K	–	122
2019 Q4	$20K	Buy	+600	New	+$19.1K	0.01%	271

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Anfield Capital Management's ARKG Position: Q1 2026 in Review

Anfield Capital Management held its ARK Genomic Revolution ETF (ARKG) position steady in Q1 2026 at 301 shares worth $7.95K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Anfield Capital Management first reported a position in ARKG in Q4 2019 and has held it in 16 quarters since. The position peaked at $2.71M in Q4 2020. 219 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Anfield Capital Management held 301 shares of ARK Genomic Revolution ETF worth $7.95K as of Q1 2026.
Anfield Capital Management left its ARK Genomic Revolution ETF share count unchanged in Q1 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #464 holding.
Anfield Capital Management first reported a position in ARK Genomic Revolution ETF in Q4 2019 and has held it in 16 quarters since.
Anfield Capital Management's ARK Genomic Revolution ETF position peaked at $2.71M in Q4 2020.
219 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.